AlphaFold predicted structure
EEF2 · P13639

Mean pLDDT
89.8/ 100
Confident
858 residues
Confidence breakdown
- Very high(≥ 90)65%
- Confident(70–90)32%
- Low(50–70)4%
- Very low(< 50)0%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
eukaryotic translation elongation factor 2
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Fetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedHydrocephalus
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownAtaxia and cerebellar anomalies - narrow panel
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownHereditary ataxia
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownHereditary ataxia with onset in adulthood
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownDDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownspinocerebellar ataxia type 26
primary cutaneous T-cell non-Hodgkin lymphoma
neoplasm
hairy cell leukemia
neurodegenerative disease
Hydrocephalus
Parkinson disease
Alzheimer disease
acute myeloid leukemia
multiple sclerosis
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Elongation factor 2
Catalyzes the GTP-dependent ribosomal translocation step during translation elongation (PubMed:26593721). During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively (PubMed:26593721). Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome (PubMed:26593721)
EEF2 · P13639

Mean pLDDT
89.8/ 100
Confident
858 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0